Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 5/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 4/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22616946 | 0.82 | CTSL (0.46) | PRKDCGBA1CTSLCTSBCTSK | |
| SCHEMBL21664309 | 0.73 | LMNA (0.50) | PRKDCHRH1HRH3LMNAHTT | |
| SCHEMBL22616952 | 0.72 | HRH3 (0.54) | HRH3CTSLCTSBCTSKHRH4 | |
| SCHEMBL22616951 | 0.72 | HRH3 (0.54) | HRH3CTSLCTSBCTSKHRH4 | |
| SCHEMBL22623265 | 0.72 | HRH3 (0.54) | HRH3CTSLCTSBCTSKHRH4 | |
| SCHEMBL31065671 | 0.72 | NPSR1 (0.53) | PRKDCHRH1HRH3LMNAHTT | |
| SCHEMBL11015775 | 0.72 | PTK2 (0.73) | PRKDCHRH1HRH3KITPDGFRA | |
| SCHEMBL26558270 | 0.71 | LMNA (0.47) | PRKDCHRH1HRH3KITPDGFRA | |
| SCHEMBL27685353 | 0.71 | CTSK (0.56) | CTSLCTSBCTSK | |
| SCHEMBL30821993 | 0.70 | PTK2 (0.71) | PRKDCHRH1HRH3KITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213055-A1 | SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVIL ACTIVITY | UNIV VIRGINIA PATENT FOUNDATION (US) | 2022-07-07 | — | — | US | disclosed |
| US-20220213055-A1 | SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVIL ACTIVITY | UNIV VIRGINIA PATENT FOUNDATION (US) | 2022-07-07 | — | — | US | disclosed |
| EP-3962485-A1 | SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVILACTIVITY | University Of Virginia Patent Foundation (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2020223715-A1 | SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVILACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-11-05 | — | — | WO | disclosed |
| WO-2020223715-A1 | SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVILACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213055-A1 | SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVIL ACTIVITY | VCL, VPS28, HDLBP | PRKDC 2558/4885HRH1 3640/4885HRH3 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.